



Subst. Form 10-114	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Applicant: Hazen, et al.	
	Filing Date: January 2, 2002	Group: 3736

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
PN	AA	6,268,220	July 31, 2001	Heinecke			Sep. 9, 1996
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AE						
	AF						
	AG						
	AH						
	AI						

OTHER PRIOR ART

	AJ	
	AK	
	AL	
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	

RECEIVED
OCT 29 2003
10 3700 MAIL ROOM

Examiner: <i>Lawrence</i>	Date Considered: 3/19/04
---------------------------	--------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
OCT 5 1 2003
TECH CENTER 1000/2000

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

SEP 11 2002

Page 1 of 1

TECH CENTER 1600/2900

Subst. Form PTO-1449

Atty. Docket No.: 26473/04177

Serial No.: 10/039,753

APPLICANT'S INFORMATION
DISCLOSURE STATEMENT


Applicant: Hazen, et al.

Filing Date: January 2, 2002

Group: 3736

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
PN	AA	5,122,534	June 16, 1992	Loose, et al.			Jul. 10, 1991
PN	AB	5,889,042	March 30, 1999	MacLean, et al.			Feb. 21, 1997
	AC						
	AD						



FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translation?
AE						
AF						
AG						
AH						
AI						

RECEIVED
AUG 23 2002


OTHER PRIOR ART

TECHNOLOGY CENTER R3700

PN	AJ	International Search Report dated July 31, 2002.
PN	AK	"Oxidized LDL and HDL: antagonists in atherothrombosis" by Mertens, et al., <u>FASEB J.</u> , 15, 2073-2084 (2001).
PN	AL	"Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species" by Podrez, et al., <u>J. Clin. Invest.</u> , 105:1095-1108 (2000).
PN	AM	"Inhibition of Adhesion Molecules Markedly Ameliorates Cytokine-Induced Sustained Myocardial Dysfunction in Dogs <i>in vivo</i> " by Momii, et al., <u>J. Mol. Cell. Cardiol.</u> , 30, 2637-2650 (1998).
PN	AN	"Supplementation with Tetrahydrobiopterin Suppresses the Development of Hypertension in Spontaneously Hypertension Rats" by Hong, et al., <u>Hypertension</u> , 2001; 38:1044-1048.
	AO	
	AP	
	AQ	
	AR	

Examiner: *Patricia J. Nor*Date Considered: *3/19/02*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS
ORIGINALLY FILED

Page 1 of 1

Subst. Form PTO-1449 APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
	Applicant: Hazen, et al. Filing Date: January 2, 2002	

RECEIVED
AUG 14 2002
TECHNOLOGY CENTER-R3700

Group: 3736

U.S. PATENT DOCUMENTS

Initial*	Document No.	Date	Name	Class	Subcl.	Filing Date
AA						
AB						
AC						
AD						

RECEIVED
AUG 26 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translation?
AE						
AF						
AG						
AH						
AI						

OTHER PRIOR ART

PN	AJ	"Myeloperoxidase Deficiency" by Nauseef, <i>Hematology, Oncology Clinics of North America</i> , Vol. 2, No. 1, March 1988, pp. 135-158.
	AK	"Primary Inherited Defects in Neutrophil Function: Etiology and Treatment" by Malech, et al., <i>Seminars in Hematology</i> , Vol. 34, No. 4, October, 1997, pp. 279-290.
	AL	"Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall" by Heinecke, et al., <i>FASEB J.</i> , 13, 1113-1120 (1999).
	AM	"Myeloperoxidase-Generated Oxidants and Atherosclerosis" by Podrez, et al., <i>Free Radical Biology & Medicine</i> , Vol. 28, No. 12, pp. 1717-1725, January, 2000.
	AN	"Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerosis Lesions" by Daugherty, et al., <i>J. Clin. Invest.</i> , Vol. 94, July 1994, 437-444.
	AO	"3-Chlorotyrosine, a Specific Marker of Myeloperoxidase-catalyzed Oxidation, Is Markedly Elevated in Low Density Lipoprotein Isolated from Human Atherosclerosis Intima" by Hazen, et al., <i>J. Clin. Invest.</i> , Vol. 99, No. 9, May, 1997, 2075-2081.
	AP	"Elevated levels of protein-bound <i>p</i> -hydroxyphenylacetaldehyde, an amino acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerosis lesions" by Hazen, et al., <i>Biochem J.</i> (2000) 352, 693-699.
PN	AQ	" <i>p</i> -Hydroxyphenylacetaldehyde, an Aldehyde Generated by Myeloperoxidase, Modifies Phospholipid Amino Groups of Low Density Lipoprotein in Human Atherosclerosis Intima" by Heller, et al., <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 14, April 7, 2000, pp. 9957-9962.
	AR	

Examiner: *fax/vr*

Date Considered: *3/19/05*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS
ORIGINALLY FILED

Page 1 of 1

Subst. Form PTO-1449	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Applicant: Hazen, et al.	
	Filing Date: January 2, 2002	Group: 3736

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA						
	AB						
	AC						
	AD						

RECEIVED

AUG - 7 2002

TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS


		Document No.	Date	Country	Class	Subcl.	Translation?
	AE						
	AF						
	AG						
	AH						
	AI						

OTHER PRIOR ART

PN	AJ	"Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease" by Zhang, et al., <u>JAMA</u> , Vol. 286, No. 17, November 7, 2001, pp. 2136-2142.
PN	AK	"Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis? Do the Antioxidant Trials Conducted to Date Refute the Hypothesis?" by Steinberg, et al., <u>Circulation</u> , 2002; 105:2107-2111.
	AL	
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
Examiner:	Date Considered: 5/19/02	

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
AUG 22 2002
TECH CENTER 1600/2900



Subst. Form PTO-1449 APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
	Applicant: Hazen, et al.	
	Filing Date: January 2, 2002	Group: 3736

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
PN	AE	0 389 381	September 26, 1990	EP			
PN	AF	02/50550	June 27, 2002	WO			
	AG						
	AH						
	AI						

OTHER PRIOR ART

	AJ	Supplementary European Search Report dated January 29, 2004.
PN	AK	"Kinetics of Oxidation of Tyrosine and Dityrosine by Myeloperoxidase Compounds I and II" by Marquez, et al., <u>The Journal of Biological Chemistry</u> , Vol. 270, No. 51, December 22, 1995, pp. 30434-30440.
PN	AL	"Leukocytes Utilize Myeloperoxidase-Generated Nitrating Intermediates as Physiological Catalysts for the Generation of Biologically Active Oxidized Lipids and Sterols in Serum" by Schmitt, et al., <u>Biochemistry</u> , 1999, 38, 16904-16915.
PN	AM	"Nitric Oxide Modulates the Catalytic Activity of Myeloperoxidase" by Abu-Soud, et al., <u>The Journal of Biological Chemistry</u> , Vol. 275, No. 8, February 25, 2000, pp. 5425-5430.
	AN	
	AO	
	AP	
	AQ	
	AR	
Examiner:	Date Considered: 3/19/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.